CTOs on the Move

MedSpeed

www.medspeed.com

 
Healthcare is changing. Healthcare organizations are growing. Care continues to expand outside of the hospital walls. This provides more capacity to utilize scale to create healthcare companies that are better functioning, smarter organizations. Intra-company logistics - the enterprise-wide movement of physical materials, such as blood and specimens, pharmaceuticals and supplies - is the foundation of the healthcare supply chain. Healthcare organizations, especially those providing service to patients` homes, need transportation to function. With 130+ locations in 29 states, MedSpeed is the market-leading organization that is changing the way the healthcare industry views transportation by leveraging it to help organizations integrate ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.medspeed.com
  • 140 Industrial Drive
    Elmhurst, IL USA 60126
  • Phone: 630.617.5050

Executives

Name Title Contact Details
Jim Van Duyn
Chief Information Officer Profile

Similar Companies

Crothall Services Group

Crothall provides optimal laundry and linen services, both in the laundries that we own as well as those that we manage and operate. It is our depth of management expertise, along with our unyielding commitment to quality and customer service, which has

Community Interface Services

Community Interface Services is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Management Services

Medical Management Services is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Devereux

Devereux Advanced Behavioral Health is one of the largest and most advanced behavioral healthcare organizations in the country. Informed by the latest advancements in science and medicine, we combine evidence-based interventions with compassionate family engagement to help change lives. We were founded in 1912 by special education pioneer, Helena Devereux. Today, Devereux is a national nonprofit partner for individuals, families, schools and communities, serving many of the most vulnerable members of our society in areas of autism, intellectual and developmental disabilities, specialty mental health, and child welfare. Our Mission: Devereux Advanced Behavioral Health changes lives – by unlocking and nurturing human potential in people living with emotional, behavioral or cognitive differences. Devereux Advanced Behavioral Health employs more than 7,500 staff and operates 15 centers in 13 states. We offer a comprehensive national network of clinical, therapeutic, educational, and employment programs and services that positively impact the lives of tens of thousands of children, adults – and their families – every year. Our Culture, Our Expectations At Devereux, we strive to incorporate servant leadership into our culture and every aspect of our organizational framework; from the delivery of quality services to individuals served, their families, and other stakeholders to the development and empowerment of our employees. We offer challenging and exciting work, and our supportive team environment creates an empowering and positive atmosphere. To be successful in our work environment, you will put the needs of others first, and will feel called to serve, and called to lead.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.